Synlogic Overview
Synlogic (SYBX) has a ROE of -5.45%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-5.45%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Synlogic (SYBX) currently reports a ROE of -5.45%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Synlogic's ROE history and peer comparisons.
Synlogic's ROE of -5.45% is higher than the Healthcare sector average of -100.59%. That is roughly 94.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Synlogic's current -5.45% should be judged against Healthcare norms (sector average: -100.59%) and against SYBX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -5.45%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Synlogic, and consider following SYBX for alerts when major investors trade the stock.
Synlogic is classified in the Healthcare sector. On ROE, it currently shows -5.45% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SYBX with unrelated industries.
